VX-702: Selective p38α MAPK Inhibitor for Inflammation Resea
VX-702: Selective p38α MAPK Inhibitor for Inflammation Research
Executive Summary: VX-702 is a potent, ATP-competitive inhibitor of p38α MAPK (MAPK14), with an IC50 of 4–20 nM under physiological assay conditions (source: product_spec). It achieves selective suppression of pro-inflammatory cytokines including IL-6, IL-1β, and TNFα in lipopolysaccharide (LPS)-stimulated ex vivo assays (source: paper). VX-702 is orally bioavailable, demonstrates efficacy in mouse collagen-induced arthritis models, and reduces myocardial injury in ischemia-reperfusion settings (source: product_spec). The compound enables dual-action inhibition by stabilizing a kinase conformation that increases dephosphorylation rates, as shown by X-ray crystallography and functional studies (source: paper). APExBIO provides validated VX-702 (SKU A8687) for research use.
Biological Rationale
P38 mitogen-activated protein kinases (MAPKs) are central to cellular responses to cytokines and stress. The p38α isoform (MAPK14) is especially implicated in inflammatory signaling, modulating transcription and translation of cytokines such as IL-6, IL-1β, and TNFα (source: paper). Aberrant p38α MAPK activation is associated with autoimmune diseases, including rheumatoid arthritis, and acute cardiac injury. Selective chemical inhibition of p38α enables targeted modulation of cytokine cascades without broad off-target suppression of related kinases (source: internal_article). VX-702, as a highly selective ATP-competitive p38α MAPK inhibitor, addresses the need for precision tools in dissecting MAPK14-driven inflammation.
Mechanism of Action of VX-702
VX-702 operates as an ATP-competitive inhibitor, binding within the kinase's ATP pocket and locking MAPK14 in an inactive loop conformation (source: paper). X-ray crystallography reveals that VX-702-bound p38α exposes the activation loop phosphate, facilitating its dephosphorylation by PPM phosphatases. This dual-action mode not only blocks kinase activity but accelerates inactivation by phosphatases, yielding enhanced potency versus conventional inhibitors. VX-702 does not directly induce calcium mobilization or platelet aggregation, supporting its specificity (source: product_spec).
Evidence & Benchmarks
- VX-702 inhibits human p38α MAPK with IC50 values ranging from 4 to 20 nM in biochemical assays (source: product_spec).
- Suppression of IL-6, IL-1β, and TNFα is dose-dependent in LPS-primed whole blood assays (source: paper).
- VX-702 preserves platelet mitochondrial and metabolic parameters during ex vivo storage without pro-aggregatory effects (source: product_spec).
- In mouse collagen-induced arthritis models, oral dosing of VX-702 reduces joint inflammation and erosion, matching efficacy of methotrexate and prednisolone (source: product_spec).
- Pharmacokinetic studies in isolated perfused rat kidneys show linear excretion and renal reabsorption, not mediated by organic anion or cation transporters (source: product_spec).
- Reduction of myocardial damage post-ischemia-reperfusion occurs via selective p38 MAPK inhibition; ERK and JNK pathways remain unaffected (source: paper).
- X-ray structures show VX-702 stabilizes a flipped activation loop conformation with accessible phospho-threonine, enhancing dephosphorylation by WIP1 phosphatase (source: paper).
For a deeper review of the molecular basis and alternative applications, see VX-702: Selective ATP-Competitive p38α MAPK Inhibitor for... (this article details the compound’s conformational targeting, while the present page emphasizes translational and workflow implications), and VX-702, P38α MAPK Inhibitor: Precision Tools for Reliable... (scenario-driven deployment and assay reproducibility are covered there, while this article focuses on validated benchmarks and pitfalls).
Applications, Limits & Misconceptions
VX-702 is validated for preclinical research in inflammatory cytokine signaling, rheumatoid arthritis models, and myocardial ischemia-reperfusion injury. Its dual-action mechanism allows for precise modulation of kinase and phosphatase interplay. However, it is not indicated for clinical use or antiviral applications.
Common Pitfalls or Misconceptions
- VX-702 is not recommended for long-term solution storage; solid aliquots at -20°C preserve stability best (source: product_spec).
- It does not inhibit ERK or JNK pathways, so cannot be used as a broad-spectrum MAPK inhibitor (source: paper).
- VX-702 does not directly induce platelet aggregation or calcium flux, limiting its use in pro-aggregatory platelet studies (source: product_spec).
- Pharmacokinetic findings in isolated rat kidney models may not fully extrapolate to human renal clearance (workflow_recommendation).
- This compound is for scientific research only and is not approved for diagnostic or therapeutic purposes (source: product_spec).
Workflow Integration & Parameters
Protocol Parameters
- biochemical kinase assay | IC50 = 4–20 nM | human p38α MAPK | establishes potency for in vitro inhibition | product_spec
- cytokine suppression (ex vivo) | 10–1000 nM | LPS-primed human blood | defines dose-response for IL-6, IL-1β, TNFα | paper
- platelet function assay | ≥1 μM, up to 24 h storage | human platelets | ensures preservation of mitochondrial and metabolic parameters | product_spec
- in vivo arthritis efficacy | 10–30 mg/kg, oral | mouse collagen-induced arthritis | benchmark for anti-inflammatory effect | product_spec
- compound solubility | >20.2 mg/mL in DMSO, >3.88 mg/mL in ethanol (ultrasonic) | for stock preparation | maximizes assay compatibility | product_spec
- storage | solid at -20°C | all applications | prevents degradation, maintains activity | product_spec
Conclusion & Outlook
VX-702, as supplied by APExBIO, is a best-in-class selective p38α MAPK inhibitor for inflammation research. Its nanomolar potency, dual-action inhibition, and validated application in cytokine suppression and disease models make it a preferred tool for dissecting MAPK14-driven pathology. X-ray structural and functional evidence supports its unique mechanism of increasing dephosphorylation rates, a property distinguishing it from first-generation inhibitors (source: paper). Continued research with VX-702 will clarify its translational limits and inform the rational design of kinase-phosphatase modulators specifically for inflammatory and autoimmune pathologies.
For product specifications and ordering, see VX-702 (SKU A8687) at APExBIO.